Kronos Bio Enters Deal to be Acquired by Concentra Biosciences; Shares Fall

MT Newswires Live

05/02

Kronos Bio (KRON) said Thursday it agreed to be acquired by Concentra Biosciences for $0.57 in cash per share, plus a non-tradeable contingent value right.

The CVR entitles holders to potential future payments based on the proceeds from certain asset dispositions and realized cost savings, subject to specific terms laid out in the agreement.

A Concentra subsidiary is expected to commence a tender offer by May 15.

The transaction is anticipated to close by mid-2025, Kronos Bio said.

Shares of Kronos were down nearly 23% in recent trading.

Price: 0.69, Change: -0.20, Percent Change: -22.64

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2532288592"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532288592\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2532288592?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 01:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532288592","market":"hk","top_or_hot":-1,"title":"Kronos Bio Enters Deal to be Acquired by Concentra Biosciences; Shares Fall","media":"MT Newswires Live","content":"<html><body><p> Kronos Bio (KRON) said Thursday it agreed to be acquired by Concentra Biosciences for $0.57 in cash per share, plus a non-tradeable contingent value right.</p><p>The CVR entitles holders to potential future payments based on the proceeds from certain asset dispositions and realized cost savings, subject to specific terms laid out in the agreement.</p><p>A Concentra subsidiary is expected to commence a tender offer by May 15.</p><p>The transaction is anticipated to close by mid-2025, Kronos Bio said.</p><p>Shares of Kronos were down nearly 23% in recent trading.</p><p>Price: 0.69, Change: -0.20, Percent Change: -22.64</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kronos Bio Enters Deal to be Acquired by Concentra Biosciences; Shares Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKronos Bio Enters Deal to be Acquired by Concentra Biosciences; Shares Fall\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-05-02 01:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Kronos Bio (KRON) said Thursday it agreed to be acquired by Concentra Biosciences for $0.57 in cash per share, plus a non-tradeable contingent value right.</p><p>The CVR entitles holders to potential future payments based on the proceeds from certain asset dispositions and realized cost savings, subject to specific terms laid out in the agreement.</p><p>A Concentra subsidiary is expected to commence a tender offer by May 15.</p><p>The transaction is anticipated to close by mid-2025, Kronos Bio said.</p><p>Shares of Kronos were down nearly 23% in recent trading.</p><p>Price: 0.69, Change: -0.20, Percent Change: -22.64</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRON","symbol_name":"Kronos Bio, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2532288592","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532288592","pubTimestamp":1746120341,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kronos Bio  said Thursday it agreed to be acquired by Concentra Biosciences for $0.57 in cash per share, plus a non-tradeable contingent value right.The CVR entitles holders to potential future payments based on the proceeds from certain asset dispositions and realized cost savings, subject to specific terms laid out in the agreement.A Concentra subsidiary is expected to commence a tender offer by May 15.The transaction is anticipated to close by mid-2025, Kronos Bio said.Shares of Kronos were down nearly 23% in recent trading.Price: 0.69, Change: -0.20, Percent Change: -22.64","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRON":"Kronos Bio, Inc.","BK4505":"高瓴资本持仓","BK4139":"生物科技","BK4090":"商品化工","KRO":"康诺斯全球"},"translate_title":"Kronos Bio达成协议，被Concentra Biosciences收购；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRO":1,"KRON":1},"content_text":"Kronos Bio (KRON) said Thursday it agreed to be acquired by Concentra Biosciences for $0.57 in cash per share, plus a non-tradeable contingent value right.The CVR entitles holders to potential future payments based on the proceeds from certain asset dispositions and realized cost savings, subject to specific terms laid out in the agreement.A Concentra subsidiary is expected to commence a tender offer by May 15.The transaction is anticipated to close by mid-2025, Kronos Bio said.Shares of Kronos were down nearly 23% in recent trading.Price: 0.69, Change: -0.20, Percent Change: -22.64","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}